The historical rank and industry rank for MindWalk Holdings's Net Margin % or its related term are showing as below:
HYFT'
s Net Margin % Range Over the Past 10 Years
Min: -204.65 Med: -95.04 Max: -35.19
Current: -43.83
HYFT's Net Margin % is ranked better than 56.81% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs HYFT: -43.83
MindWalk Holdings (NAS:HYFT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
MindWalk Holdings Net Margin % Related Terms
MindWalk Holdings Net Margin % Historical Data
* Premium members only.
The historical data trend for MindWalk Holdings's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MindWalk Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindWalk Holdings Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindWalk Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where MindWalk Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindWalk Holdings (HYFT) has a Net Margin % of -94.53% as of Jan. 2026. Net margin is the ratio of total net income to net sales. View historical data on MindWalk Holdings and its competitors. According to the industry distribution chart, MindWalk Holdings ranks #409 out of 947 companies in the Biotechnology industry, placing it in the top 43.2%.
Is MindWalk Holdings' Net Margin % too high?
MindWalk Holdings' current Net Margin % is -94.53%. Based on the distribution chart, MindWalk Holdings ranks #409 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MindWalk Holdings has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MindWalk Holdings' Net Margin % compare to GANX and EXOZ?
According to the Biotechnology industry distribution chart, MindWalk Holdings ranks #409 out of 947 companies for Net Margin %. This puts MindWalk Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on MindWalk Holdings and its competitors. MindWalk Holdings's current Net Margin % is -94.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindWalk Holdings stock overvalued right now?
Based on GuruFocus' analysis, MindWalk Holdings (HYFT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.61, compared to a current price of $1.52 — trading 149.2% above its estimated fair value. The current Net Margin % is -94.53%. MindWalk Holdings' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For MindWalk Holdings (HYFT), the current Net Margin % is -94.53% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MindWalk Holdings (HYFT) Overvalued in 2026?
Based on GuruFocus' analysis, MindWalk Holdings stock appears to be overvalued.
The current stock price of $1.52 is trading 149.2% above its estimated GF Value™ of $0.61.
GuruFocus considers MindWalk Holdings to be Significantly Overvalued.
Key valuation signals for HYFT:
Net Margin %: -94.53%
GF Value™: $0.61 vs. price of $1.52 (149.2% above fair value)
No single metric tells the full story. See the HYFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
38GF Score
Get the complete analysis for HYFT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYFT has been successfully added to your 
